4th Annual CKD Drug Development Summit
1-3 March, 2022
Boston, USA
ENYO attended the 4th Chronic Kidney Disease Drug Development Summit, the only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. We presented a poster entitled “VONAFEXOR induces renal and hepatic improvements in NASH-LIVIFY trial results”.
Tech Tour Growth & EIC ScalingUP 2022
28 Feb-4 March 2022
Digital event
Jacky Vonderscher presented ENYO Pharma and gave a pitch in the “Biotech, Pharma, Therapeutics” session in front of strategic investors & partners among the top 50 European deep tech growth companies funded by EIC.
https://techtour.com/events/2022/2/event-tech-tour-growth–eic-scalingup-2022%5B2%5D.html
ENYO Pharma in the Top 50 of the EIC ScalingUp List
ENYO Pharma is in the Top 50 of the EIC ScalingUp List, in the Health Track. We were selected out of a universe of 3,000+ deeptech startups, as funded so far by the European Innovation Council (EIC) or SME Instrument. This is a fantastic business support for the growth of the company during this pivotal year.
5th NASH Summit 2021
November 29 – December 2, 2021
100% digital
Dr Pietro Scalfaro, CMO of the company, will present latest Vonafexor data at the 5th NASH Summit. This conference aims at deepening understanding of early, translational and late stage clinical science to support NASH candidate entry to market.
Selection in the Best of the Liver Meeting 2021
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.
Latest Press Release 